Drug Trial Radar · NCT01518998
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Aug 2011
Primary completion
Oct 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Gachon University Gil Medical Center; The Catholic University of Korea; Kyungpook National University Hospital; Daegu Catholic University Medical Center; Wonkwang University Hospital; Wonju Severance Christian Hospital; Korea University Guro Hospital; DongGuk University; Yeungnam University Hospital; Chonnam National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chungnam National University; Asan Medical Center; Seoul National University Bundang Hospital; Inha University Hospital; Seoul National University Hospital; Inje University; Samsung Medical Center; Pusan National University Yangsan Hospital; Soon Chun Hyang University; Catholic University of Korea Saint Paul's Hospital; Hallym University Kangnam Sacred Heart Hospital; Jeju National University Hospital; Hanyang University Seoul Hospital; Kangbuk Samsung Hospital
- First posted
- Jan 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
Conditions
- Hypertension
Interventions
Fimasartan , Amlodipine, PlaceboDrug
Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sitting Diastolic Blood PressureTime frame: 8weeks from baseline visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.